港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,772.232

+40.7992.36%

漲家數：7

跌家數：- -

平家數：1

市盈率：- -

高：1,805.863

開：1,735.522

低：1,735.522

收：1,731.433

資料載入中...

總覽新聞資訊

泰格醫藥(03347)截至2月末累計回購980.63萬A股

我武生物(300357.SZ)：皮炎診斷貼劑02貼藥物臨牀試驗申請獲得受理

維亞生物03月04日主力淨流出121萬元散户資金買入

泰格醫藥03月04日遭主力拋售345萬元

藥明生物03月04日主力淨流入1627萬元散戶資金拋售

藥明康德03月04日獲主力加倉623萬元

天壇生物(600161.SH)下屬公司“人凝血因子Ⅸ”將開展Ⅲ期臨牀試驗

復星醫藥：24價肺炎球菌多糖結合疫苗臨牀試驗獲批

復星醫藥(600196.SH)子公司獲24價肺炎疫苗臨牀試驗批准

復星醫藥：控股子公司獲24價肺炎球菌多糖結合疫苗臨牀試驗批准

康緣藥業(600557.SH)：固本消疹顆粒獲得藥物臨牀試驗批准

康緣藥業(600557.SH)：淫羊藿總黃酮膠囊新增血管性痴呆適應症臨牀試驗獲批

泰格醫藥(300347.SZ)已耗資約5億元回購股份980.63萬股

滬深300製藥與生物科技指數報7436.24點，前十大權重包含藥明康德等

江蘇恩華藥業股份有限公司藥品申請臨牀試驗默示許可獲受理

阿斯利康全球研發（中國）有限公司藥品申請臨牀試驗默示許可獲受理

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1772.232,"timestamp":1741248510306,"preClose":1731.4331,"halted":0,"volume":100037287,"delay":0,"changeRate":0.023564,"change":40.79895,"pbRate":2.569388,"amount":2232823119,"amplitude":0.040626,"prevYearClose":1395.7731,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"turnoverRate":0.00862,"marketCap":380565866496,"floatMarketCap":164754930944,"peRate":32.042796},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1805.8632,"amplitude":0.040626,"preClose":1731.4331,"low":1735.5215,"pbRate":"2.569388","latestPrice":1772.232,"volume":100037287,"delay":0,"open":1735.5215,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"sixtyDayClose":1360.467,"secType":"PLATE","market":"HK","turnoverRate":0.00862,"peRate":32.042796,"marketCap":380565866496,"floatMarketCap":164754930944,"timestamp":1741248510306,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516626708","title":"泰格醫藥(03347)截至2月末累計回購980.63萬A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516626708","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516626708?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 18:07","pubTimestamp":1741082848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，截至2025年2月28日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份980.63万股，占公司总股本的比例为1.1337%，占公司A股总股本比例为1.3219%，最高成交价为62.00元/股，最低成交价为48.17元/股，成交总金额为5亿元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0216","03347","LU1820825898.SGD","159982","LU1146622755.USD","BK1583","300347","BK1576","BK0028","399300","BK1141","BK0174"],"gpt_icon":0},{"id":"2516416623","title":"我武生物(300357.SZ)：皮炎診斷貼劑02貼藥物臨牀試驗申請獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516416623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516416623?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:41","pubTimestamp":1741081267,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)公告，公司获得国家药品监督管理局发出的《受理通知书》，由公司提交的“皮炎诊断贴剂02贴”药物临床试验申请已获得正式受理。相关适应症为：用于斑贴试验，辅助诊断与卡松、对苯二胺、甲醛致敏相关的变应性接触性皮炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357","BK0028","BK1576","BK1141","03347","BK1583","BK0239"],"gpt_icon":0},{"id":"2516625115","title":"維亞生物03月04日主力淨流出121萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2516625115","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516625115?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:39","pubTimestamp":1741081161,"startTime":"0","endTime":"0","summary":"03月04日, 维亚生物股价跌3.03%，报收1.28元，成交金额682万元，换手率0.25%，振幅9.09%，量比0.78。维亚生物今日主力资金净流出121万元，上一交易日主力净流出0万元。该股近5个交易日下跌6.57%，主力资金累计净流出179万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2054万元，其中净流入天数为12日。该股主力净额占比0.04%，港股市场排名2556/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174744a25ea6d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174744a25ea6d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01873","BK1141","BK1576"],"gpt_icon":0},{"id":"2516625402","title":"泰格醫藥03月04日遭主力拋售345萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516625402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516625402?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:39","pubTimestamp":1741081148,"startTime":"0","endTime":"0","summary":"03月04日, 泰格医药股价跌0.60%，报收33.10元，成交金额7877万元，换手率1.94%，振幅3.90%，量比0.49。泰格医药今日主力资金净流出345万元，连续4日净流出，上一交易日主力净流出58万元。近一年数据显示，该股主力连续4日净流出后，次日下跌概率为75.00%，平均跌幅为7.10%。该股近5个交易日下跌5.14%，主力资金累计净流出323万元；近20日主力资金累计净流入1193万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174649a25ea632&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174649a25ea632&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2516254506","title":"藥明生物03月04日主力淨流入1627萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2516254506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516254506?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:38","pubTimestamp":1741081087,"startTime":"0","endTime":"0","summary":"03月04日, 药明生物股价涨0.89%，报收22.60元，成交金额6.62亿元，换手率0.72%，振幅4.69%，量比0.45。药明生物今日主力资金净流入1627万元，上一交易日主力净流出1738万元。该股近5个交易日下跌3.21%，主力资金累计净流出1.90亿元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入8.44亿元，其中净流入天数为11日。该股主力净额占比0.02%，港股市场排名219/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174057abe79202&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174057abe79202&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456846285.SGD","LU0327786744.USD","LU1242518857.USD","LU1880383366.USD","LU0417516902.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0359201612.USD","LU1242518931.SGD","BK1589","LU1688375341.USD","SG9999002562.SGD","BK1610","LU0348735423.USD","LU0320764599.SGD","LU0417516738.SGD","LU0516422440.USD","IE00B0JY6N72.USD","LU0307460666.USD","LU0819121731.USD","LU0516423091.SGD","LU0140636845.USD","LU0348825331.USD","LU0708995583.HKD","LU1794554557.SGD","LU0516422366.SGD","LU0856984785.SGD","LU0043850808.USD","02269","LU0326950275.SGD","LU0359202008.SGD","LU0039217434.USD","LU0823426480.USD","BK1141","LU0181495838.USD","LU0456827905.SGD","LU0051755006.USD","LU0588546209.SGD","LU2039709279.SGD","LU0052750758.USD","LU1720050803.USD","LU0823426308.USD","BK1576","SG9999002463.SGD","LU0516423174.USD","LU0979878070.USD","BK1521"],"gpt_icon":0},{"id":"2516254656","title":"藥明康德03月04日獲主力加倉623萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516254656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516254656?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:37","pubTimestamp":1741081046,"startTime":"0","endTime":"0","summary":"03月04日, 药明康德股价涨1.18%，报收59.80元，成交金额2.07亿元，换手率0.90%，振幅3.21%，量比0.39。药明康德今日主力资金净流入623万元，上一交易日主力净流入490万元。该股近5个交易日下跌1.98%，主力资金累计净流入231万元；近20日主力资金累计净流入1.02亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304173735abe790bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304173735abe790bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU2242644610.SGD","LU2045819591.USD","BK1576","LU0320764599.SGD","LU2125910500.SGD","LU0708995583.HKD","BK1141","02359","BK1583","LU0052750758.USD"],"gpt_icon":0},{"id":"2516623983","title":"天壇生物(600161.SH)下屬公司“人凝血因子Ⅸ”將開展Ⅲ期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516623983","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516623983?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:33","pubTimestamp":1741080792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天坛生物(600161.SH)发布公告，公司下属成都蓉生药业有限责任公司研制的“人凝血因子Ⅸ”已完成临床伦理审查、临床入组前准备等工作，将于近日正式开展Ⅲ期临床试验。上述产品在生产、上市销售前还需履行的主要程序包括：完成Ⅲ期临床试验、提交药品上市许可申请、通过国家药品监督管理局药品审评中心审评及国家药品监督管理局审批后，获得药品注册证书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0168","BK1583","600161","BK1576","03347","BK0188","BK1141","BK0239","BK0046","BK0185","BK0010","BK0028","BK0082"],"gpt_icon":0},{"id":"2517605039","title":"復星醫藥：24價肺炎球菌多糖結合疫苗臨牀試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2517605039","media":"E公司","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517605039?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:09","pubTimestamp":1741079346,"startTime":"0","endTime":"0","summary":"人民财讯3月4日电，复星医药(600196)3月4日晚间公告，控股子公司复星安特金（成都）生物制药有限公司（简称“复星安特金”）于近日收到国家药品监督管理局关于24价肺炎球菌多糖结合疫苗的临床试验批准。复星安特金拟于条件具备后于中国境内（不包括港澳台地区）开展该疫苗的I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304170906989b4833&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304170906989b4833&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1576","BK1141","BK1583","BK1191","BK1593","02196","03347"],"gpt_icon":0},{"id":"2516404936","title":"復星醫藥(600196.SH)子公司獲24價肺炎疫苗臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516404936","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516404936?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 17:01","pubTimestamp":1741078876,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，公司控股子公司复星安特金(成都)生物制药有限公司于近日收到国家药品监督管理局关于24价肺炎球菌多糖结合疫苗的临床试验批准。复星安特金拟于条件具备后于中国境内开展该疫苗的I期临床试验。该疫苗采用集团拥有自主知识产权的平台技术将多糖抗原与载体蛋白结合，可以在6周龄及以上人群体内诱导产生针对多糖的T细胞依赖性免疫应答及免疫记忆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK0096","600196","BK1593","BK1191","BK0187","BK1515","BK0175","159646","BK1583","BK0239","BK0060","BK0012","BK1141","BK0183","BK1576","BK0196","02196","03347"],"gpt_icon":0},{"id":"2516664039","title":"復星醫藥：控股子公司獲24價肺炎球菌多糖結合疫苗臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516664039","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516664039?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 16:59","pubTimestamp":1741078785,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0188","03347","BK1191","BK1515","BK0060","BK0175","BK0239","BK1593","BK0012","02196","BK0196","BK0096","BK1141","BK1583","BK0028","BK0183","BK1576","159646","BK0187","600196"],"gpt_icon":0},{"id":"2516397640","title":"康緣藥業(600557.SH)：固本消疹顆粒獲得藥物臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516397640","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516397640?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 16:58","pubTimestamp":1741078724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康缘药业 发布公告，公司近日收到国家药品监督管理局签发的固本消疹颗粒《药物临床试验批准通知书》。据悉，固本消疹颗粒处方源于临床经验方。公司在收到固本消疹颗粒临床试验通知书后，需根据通知书以及新药开发及药品注册法规要求，开展并完成Ⅱ期、Ⅲ期临床试验后，整合申报资料申报产品上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600557","BK0188","BK1576","BK1141","BK0239","BK1583","03347","BK0028"],"gpt_icon":0},{"id":"2516366640","title":"康緣藥業(600557.SH)：淫羊藿總黃酮膠囊新增血管性痴呆適應症臨牀試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2516366640","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516366640?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 16:55","pubTimestamp":1741078501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康缘药业 发布公告，公司控股子公司江苏康缘阳光药业有限公司近日收到国家药品监督管理局签发的关于淫羊藿总黄酮胶囊新增血管性痴呆适应症的《药物临床试验批准通知书》。截止目前，公司对淫羊藿总黄酮胶囊上述新增适应症的累计研发投入约为215万元。公司在收到淫羊藿总黄酮胶囊临床试验通知书后，需根据通知书以及新药开发及药品注册法规要求，开展并完成Ⅱ期、Ⅲ期临床试验后，整合申报资料申报药品注册证书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03347","BK1576","BK0239","BK1141","BK1583","600557","BK0028"],"gpt_icon":0},{"id":"2516408506","title":"泰格醫藥(300347.SZ)已耗資約5億元回購股份980.63萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516408506","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516408506?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 16:48","pubTimestamp":1741078111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(300347.SZ)发布公告，截至2025年2月28日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份980.63万股，占公司总股本的比例为1.1337%，占公司A股总股本比例为1.3219%，最高成交价为62.00元/股，最低成交价为48.17元/股，成交总金额为5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","LU1820825898.SGD","BK1583","BK0077","03347","BK0174","BK0028","LU1146622755.USD","300347","BK1141","BK0216"],"gpt_icon":0},{"id":"2516459226","title":"滬深300製藥與生物科技指數報7436.24點，前十大權重包含藥明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2516459226","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516459226?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 15:19","pubTimestamp":1741072746,"startTime":"0","endTime":"0","summary":"数据统计显示，沪深300制药与生物科技指数近一个月上涨3.05%，近三个月下跌4.64%，年至今下跌0.11%。沪深300行业指数系列分别以进入各一级、二级、三级、四级行业的全部证券作为样本编制指数，形成沪深300行业指数。从沪深300制药与生物科技指数持仓样本的行业来看，化学药占比39.69%、制药与生物科技服务占比23.21%、中药占比19.52%、生物药品占比17.58%。在样本公司有特殊事件发生，导致其行业归属发生变更时，将对沪深300行业指数样本进行相应调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04151948506040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0052750758.USD","LU0708995583.HKD","LU2125910500.SGD","LU2045819591.USD","02359","000001.SH","BK1191","BK1576","LU1046422090.SGD","LU1997245177.USD","LU1997245094.SGD","CHAD","399300","159919","BK1583","CHAU","BK1141","159837","01477","BK1574","BK0216","LU2242644610.SGD","LU0320764599.SGD","LU0456842615.SGD","603259","LU2488822045.USD"],"gpt_icon":0},{"id":"2516712616","title":"江蘇恩華藥業股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516712616","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516712616?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，江苏恩华药业股份有限公司联合申请药品“盐酸他喷他多口服溶液”，获得临床试验默示许可，受理号CYHL2400265。江苏恩华药业股份有限公司，成立于1999年，位于徐州市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，江苏恩华药业股份有限公司共对外投资了21家企业，参与招投标项目4477次，知识产权方面有商标信息398条，专利信息257条，此外企业还拥有行政许可655个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","002262","BK0188","BK1576","BK0070","03347","BK1583","BK0239"],"gpt_icon":0},{"id":"2516661606","title":"阿斯利康全球研發（中國）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661606","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661606?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，阿斯利康全球研发（中国）有限公司、阿斯利康制药有限公司、上海合全医药有限公司联合申请药品“Ceralasertib薄膜包衣片”，获得临床试验默示许可，受理号CXHB2400299。阿斯利康全球研发（中国）有限公司，成立于2021年，位于上海市，是一家以从事研究和试验发展为主的企业。主要股东信息显示，阿斯利康全球研发（中国）有限公司由阿斯利康大陆有限公司 ASTRAZENECA CONTINENT B.V.持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2456880835.USD","BK4588","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK1583","BK4568","LU2462157665.USD","BK1576","BK4007","LU0889565916.HKD","BK1141","03347","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":4,"totalSize":219}]}}